Pub Date : 2017-07-17DOI: 10.1017/S0022215117001487
L M Flood
{"title":"BALLENGER'S OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY , 18th edn P A Wackym , J B Snow People's Medical Publishing House, 2016 ISBN 978 1 60795 177 3 pp 1523 Price £275.00","authors":"L M Flood","doi":"10.1017/S0022215117001487","DOIUrl":"https://doi.org/10.1017/S0022215117001487","url":null,"abstract":"","PeriodicalId":22781,"journal":{"name":"The Journal of Laryngology & Otology","volume":"65 1","pages":"937 - 938"},"PeriodicalIF":0.0,"publicationDate":"2017-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84251608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-07-17DOI: 10.1017/S0022215117001402
L. Flood
{"title":"IMPLANTABLE HEARING DEVICES C de Souza , P Roland , D L Tucci (eds) Plural Publishing, 2017 ISBN 978 1 59756 855 5 pp 288 Price US$174.95","authors":"L. Flood","doi":"10.1017/S0022215117001402","DOIUrl":"https://doi.org/10.1017/S0022215117001402","url":null,"abstract":"","PeriodicalId":22781,"journal":{"name":"The Journal of Laryngology & Otology","volume":"28 1","pages":"842 - 842"},"PeriodicalIF":0.0,"publicationDate":"2017-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72684821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-06DOI: 10.1017/S0022215117001050
L. Flood
{"title":"FLAPS: PRACTICAL RECONSTRUCTIVE SURGERY K Shokrollahi, I S Whitaker, F Nahai Thieme, 2017 ISBN 978 1 60406 715 6 pp 711 Price €279.99 £249.50","authors":"L. Flood","doi":"10.1017/S0022215117001050","DOIUrl":"https://doi.org/10.1017/S0022215117001050","url":null,"abstract":"","PeriodicalId":22781,"journal":{"name":"The Journal of Laryngology & Otology","volume":"15 1","pages":"655 - 655"},"PeriodicalIF":0.0,"publicationDate":"2017-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73998830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-05-04DOI: 10.1017/S0022215117000718
K. Khan
{"title":"RADCASES: HEAD AND NECK IMAGING G Shah , J Wesolowski , J Choi , E R Friedman (eds) Thieme, 2016 ISBN 978 1 60406 193 2 pp 224 Price £44.50","authors":"K. Khan","doi":"10.1017/S0022215117000718","DOIUrl":"https://doi.org/10.1017/S0022215117000718","url":null,"abstract":"","PeriodicalId":22781,"journal":{"name":"The Journal of Laryngology & Otology","volume":"33 1","pages":"562 - 562"},"PeriodicalIF":0.0,"publicationDate":"2017-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75012313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-05-04DOI: 10.1017/S0022215117000652
C. Leonard, C. Masih, S. McDonald, G. Taylor, N. Maiden, P. Leyden
s presented at the Laryngology and Rhinology Section Meetings, Royal Society of Medicine, 4 March 2016, London, UK Anti-tumour necrosis factor therapy is a risk factor for certain subtypes of chronic rhinosinusitis C G Leonard, C Masih, S McDonald, G Taylor, N Maiden, P J Leyden From the Craigavon Area Hospital, Northern Ireland Background There are many risk factors for chronic rhinosinusitis; however, the effect of anti-tumour necrosis factor (antiTNF) therapy has not been investigated in depth. Our experience points to a detrimental clinical effect in overall prevalence of chronic rhinosinusitis, despite its benefit in certain subtypes. Methods A telephone survey was performed to parallel the findings of the Global Allergy and Asthma European Network (‘GA2LEN’) chronic rhinosinusitis screening survey. This was itself based on the widely recognised European Position Paper on Rhinosinusitis and Nasal Polyps (‘EP3OS’) criteria. Results A total of 120 patients responded to the survey. The prevalence of chronic rhinosinusitis in the sample (anti-TNF therapy) population was 20 per cent (95 per cent confidence interval= 12.84–27.16). Anti-TNF therapy is therefore a risk factor for chronic rhinosinusitis when compared, using a one-sample test of proportions, with prevalence in the wider population. Conclusion This is the first observational study indicating increased prevalence of chronic rhinosinusitis in patients treated with anti-TNF therapy. These clinical findings require investigation in greater depth to clarify the nature of pathologies we currently diagnose and treat as chronic rhinosinusitis. Transoral partial oropharyngectomy for oropharyngeal cancer R Gan, M Nistor, G Wijayasingam, S Mortimore, M De From the Royal Derby Hospital Introduction Transoral surgery has gained popularity as a treatment of oropharyngeal cancer (Sheahan, 2015). This study aimed to analyse the oncological and survival outcomes of patients who had undergone transoral surgery for oropharyngeal cancer. Methods A retrospective study was conducted of oropharyngeal cancer patients treated with primary transoral partial oropharyngectomy between 29 August 2001 and 13 October 2015 performed by two consultants. Results Thirty-one patients were included. Seven (22.6 per cent) had stage I disease, 3 (9.7 per cent) stage II, 6 (19.4 per cent) stage III and 15 (48.4 per cent) stage IV. Twelve patients (38.7 per cent) were human papillomavirus positive. Twenty-five patients were treated with transoral laser surgery with or without neck dissection and/or chemoradiotherapy. Six patients had transoral robotic surgery with or without neck dissection and/or chemoradiotherapy. Five patients (16.1 per cent) had disease recurrence. Six patients (19.4 per cent) had positive margins on resection. The fiveyear disease-free survival rate was 78 per cent, and the disease-specific survival rates at two and five years were both 85 per cent. Five patients (16.1 per cent) died during follow up. Con
抗肿瘤坏死因子治疗是慢性鼻窦炎某些亚型的危险因素C G Leonard, C Masih, s McDonald, G Taylor, N Maiden, P J Leyden来自北爱尔兰Craigavon地区医院背景慢性鼻窦炎有许多危险因素;然而，抗肿瘤坏死因子(anti - tnf)治疗的效果尚未深入研究。我们的经验指出，尽管它对某些亚型有益，但对慢性鼻窦炎的总体患病率有不利的临床效果。方法进行电话调查，以对照全球过敏和哮喘欧洲网络(GA2LEN)慢性鼻窦炎筛查调查的结果。这本身是基于广泛认可的欧洲鼻窦炎和鼻息肉立场文件(“EP3OS”)标准。结果共120例患者参与调查。样本(抗肿瘤坏死因子治疗)人群中慢性鼻窦炎的患病率为20%(95%置信区间= 12.84-27.16)。因此，当使用单样本比例测试与更广泛人群的患病率进行比较时，抗tnf治疗是慢性鼻窦炎的危险因素。结论:这是第一个观察性研究表明，接受抗tnf治疗的患者慢性鼻窦炎患病率增加。这些临床发现需要更深入的调查，以澄清我们目前诊断和治疗的慢性鼻窦炎的病理性质。经口部分口咽切除术治疗口咽癌R Gan, M Nistor, G Wijayasingam, S Mortimore, M De来自皇家德比医院介绍经口手术作为一种治疗口咽癌的方法已经越来越受欢迎(Sheahan, 2015)。本研究旨在分析经口手术治疗口咽癌患者的肿瘤学和生存结果。方法回顾性分析2001年8月29日至2015年10月13日由2名会诊医师行经口口咽部分切除术的口咽癌患者。结果纳入31例患者。7人(22.6%)患有I期疾病，3人(9.7%)患有II期疾病，6人(19.4%)患有III期疾病，15人(48.4%)患有IV期疾病。12名患者(38.7%)呈人乳头瘤病毒阳性。25例患者行经口激光手术，伴或不伴颈部清扫和/或放化疗。6例患者行经口机器人手术，伴或不伴颈部清扫和/或放化疗。5例患者(16.1%)有疾病复发。6例患者(19.4%)切除后切缘呈阳性。5年无病生存率为78%，2年和5年疾病特异性生存率均为85%。5名患者(16.1%)在随访期间死亡。结论经口部分口咽切除术是治疗口咽癌的有效方法。炎症性鼻息肉中转化生长因子β信号的改变驱动慢性鼻窦炎伴鼻息肉的重塑N T Orban, A Eifan, M Jacobson, S Durham来自伦敦Imperial College London的介绍转化生长因子β和激活素信号的失调在下气道重塑中起着重要作用，与鼻子的相关性尚不清楚。方法对下鼻甲和鼻息肉进行免疫组化染色。在伴有鼻息肉的慢性鼻窦炎参与者(n= 10)和健康对照组(n= 19)中测量了以下变量:转化生长因子β 1;激活素a及其受体ALK-4和pSMAD2;D2-40和分化簇34(淋巴和血管重塑);平滑肌肌动蛋白和热休克蛋白47(胶原合成和肌成纤维细胞转化);基质金属蛋白酶7和9，以及它们的抑制剂组织金属蛋白酶1。
{"title":"Abstracts presented at the Laryngology and Rhinology Section Meetings, Royal Society of Medicine, 4 March 2016, London, UK","authors":"C. Leonard, C. Masih, S. McDonald, G. Taylor, N. Maiden, P. Leyden","doi":"10.1017/S0022215117000652","DOIUrl":"https://doi.org/10.1017/S0022215117000652","url":null,"abstract":"s presented at the Laryngology and Rhinology Section Meetings, Royal Society of Medicine, 4 March 2016, London, UK Anti-tumour necrosis factor therapy is a risk factor for certain subtypes of chronic rhinosinusitis C G Leonard, C Masih, S McDonald, G Taylor, N Maiden, P J Leyden From the Craigavon Area Hospital, Northern Ireland Background There are many risk factors for chronic rhinosinusitis; however, the effect of anti-tumour necrosis factor (antiTNF) therapy has not been investigated in depth. Our experience points to a detrimental clinical effect in overall prevalence of chronic rhinosinusitis, despite its benefit in certain subtypes. Methods A telephone survey was performed to parallel the findings of the Global Allergy and Asthma European Network (‘GA2LEN’) chronic rhinosinusitis screening survey. This was itself based on the widely recognised European Position Paper on Rhinosinusitis and Nasal Polyps (‘EP3OS’) criteria. Results A total of 120 patients responded to the survey. The prevalence of chronic rhinosinusitis in the sample (anti-TNF therapy) population was 20 per cent (95 per cent confidence interval= 12.84–27.16). Anti-TNF therapy is therefore a risk factor for chronic rhinosinusitis when compared, using a one-sample test of proportions, with prevalence in the wider population. Conclusion This is the first observational study indicating increased prevalence of chronic rhinosinusitis in patients treated with anti-TNF therapy. These clinical findings require investigation in greater depth to clarify the nature of pathologies we currently diagnose and treat as chronic rhinosinusitis. Transoral partial oropharyngectomy for oropharyngeal cancer R Gan, M Nistor, G Wijayasingam, S Mortimore, M De From the Royal Derby Hospital Introduction Transoral surgery has gained popularity as a treatment of oropharyngeal cancer (Sheahan, 2015). This study aimed to analyse the oncological and survival outcomes of patients who had undergone transoral surgery for oropharyngeal cancer. Methods A retrospective study was conducted of oropharyngeal cancer patients treated with primary transoral partial oropharyngectomy between 29 August 2001 and 13 October 2015 performed by two consultants. Results Thirty-one patients were included. Seven (22.6 per cent) had stage I disease, 3 (9.7 per cent) stage II, 6 (19.4 per cent) stage III and 15 (48.4 per cent) stage IV. Twelve patients (38.7 per cent) were human papillomavirus positive. Twenty-five patients were treated with transoral laser surgery with or without neck dissection and/or chemoradiotherapy. Six patients had transoral robotic surgery with or without neck dissection and/or chemoradiotherapy. Five patients (16.1 per cent) had disease recurrence. Six patients (19.4 per cent) had positive margins on resection. The fiveyear disease-free survival rate was 78 per cent, and the disease-specific survival rates at two and five years were both 85 per cent. Five patients (16.1 per cent) died during follow up. Con","PeriodicalId":22781,"journal":{"name":"The Journal of Laryngology & Otology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79775568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：